ISSN: 2550-7931

International Digital Organization for Scientific Research IDOSRJAS1012635000
IDOSR JOURNAL OF APPLIED SCIENCES 10(1):26-35, 2025.
https://doi.org/10.59298/IDOSRJAS/2025/101.263500

Pathophysiology of Benign Prostatic Hyperplasia: Cellular and Molecular Mechanisms

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Benign prostatic hyperplasia (BPH) is a prevalent condition among aging males, characterized by non-malignant enlargement of the prostate gland, which can lead to lower urinary tract symptoms (LUTS) and a significant reduction in quality of life. This review explores the cellular and molecular mechanisms underpinning the pathophysiology of BPH, highlighting the interplay of hormonal, inflammatory, and growth factor signaling pathways. Testosterone and dihydrotestosterone (DHT) serve as pivotal regulators of prostate growth, driving hyperplasia through androgen receptor-mediated transcriptional activity. Additionally, chronic inflammation, mediated by immune cell infiltration and cytokine release, contributes to tissue remodeling and stromal proliferation. Dysregulated growth factors such as fibroblast growth factors (FGFs) and transforming growth factor-beta (TGF-β) further amplify cellular proliferation and extracellular matrix deposition. Emerging evidence underscores the role of oxidative stress and mitochondrial dysfunction in exacerbating prostatic cellular senescence and genomic instability. This review also addresses the influence of stromal-epithelial interactions and the contribution of stem/progenitor cell niches in maintaining aberrant growth. Understanding these intricate mechanisms provides a foundation for identifying novel therapeutic targets aimed at mitigating BPH progression and associated symptoms.

Keywords: Benign prostatic hyperplasia, cellular mechanisms, hormonal regulation, inflammation, growth factors, molecular pathways, therapeutic targets.

INTRODUCTION

Benign Prostatic Hyperplasia (BPH) is a non-malignant enlargement of the prostate gland, commonly affecting aging males. It arises from the hyperplasia of stromal and epithelial cells within the prostate, predominantly in the periurethral region[1, 2]. The enlargement often leads to compression of the urethra, causing lower urinary tract symptoms (LUTS), which can significantly impact the quality of life by causing discomfort, sleep disturbances, and social embarrassment[3–5]. Untreated BPH may result in complications such as acute urinary retention, recurrent urinary tract infections, bladder stones, and even kidney damage due to obstructive uropathy. BPH is associated with significant healthcare costs due to frequent medical consultations, pharmacological treatments, and surgical interventions[6, 7].

BPH is one of the most prevalent conditions among aging men worldwide, affecting approximately 50% of men in their 50s and over 80% of men aged 80 and above. Studies indicate variations in the prevalence of BPH among different regions and ethnic groups, possibly influenced by genetic, lifestyle, and dietary factors. In the United States alone, BPH contributes to millions of outpatient visits annually and is one of the leading causes of urological surgeries, particularly transurethral resection of the prostate (TURP), among elderly men[8–10]. Despite decades of research, several challenges remain in fully understanding and managing BPH: pathophysiological complexity, heterogeneity in disease presentation, limited long-term efficacy of treatments, emerging role of inflammation and immunology, overlapping symptoms with other conditions, and the increasing burden of BPH due to the global increase in life expectancy. This review aims to delve into the cellular and molecular mechanisms contributing to the progression of BPH by identifying key cellular pathways, understanding cellular dynamics, bridging gaps in knowledge, and guiding future research. By integrating findings from recent research, this review will contribute to a deeper understanding of BPH progression and pave the

way for the development of novel diagnostic and therapeutic approaches.

Hormonal Regulation in BPH

Benign prostatic hyperplasia (BPH) is a nonmalignant enlargement of the prostate gland that affects aging men. Hormonal regulation plays a critical role in the development and progression of BPH, with androgens and estrogens being the principal hormones implicated in its pathogenesis. Understanding the interplay between these hormones and their receptors sheds light on the mechanisms underlying prostate growth and provides potential therapeutic targets[11]. Testosterone and Dihydrotestosterone (DHT) are pivotal in promoting prostate enlargement, while estrogens contribute through receptor-mediated effects in stromal and epithelial cells. DHT is synthesized in prostate stromal and epithelial cells by the enzyme 5α-reductase and binds to androgen receptors (ARs) with higher affinity than testosterone, initiating a cascade of transcriptional events that regulate cell proliferation and differentiation[12]. The continuous presence of DHT is essential for maintaining prostate growth, explaining the effectiveness of 5α-reductase inhibitors (e.g., finasteride) in managing BPH by reducing DHT levels and mitigating prostate enlargement. Estrogen production and sources increase in aging males due to increased aromatization of testosterone into estradiol in peripheral tissues. Estrogens influence prostate growth through two main estrogen receptors: ERα (estrogen receptor alpha) and ERβ (estrogen receptor beta). ERα signaling promotes pro-inflammatory and proliferative pathways, contributing to stromal hyperplasia and fibrosis in BPH. ERβ signaling exerts antiproliferative and anti-inflammatory effects, but loss of ERβ expression with aging disrupts the balance between proliferative and protective estrogenic actions, favoring prostatic overgrowth[13, 14].

The hormonal imbalance characterized by reduced androgen activity and heightened estrogenic influence contributes to the dysregulation of growth factors, cytokines, and extracellular matrix remodeling, driving BPH progression. The crosstalk between androgen and estrogen pathways is significant at both cellular and molecular levels, with androgens regulating the expression of genes that modulate estrogen receptor activity and estrogens influencing androgen receptor sensitivity and function. Understanding the crosstalk between these pathways has led to the development of combination therapies targeting both androgen and estrogen signaling, such as selective estrogen receptor modulators (SERMs) and 5α-reductase inhibitors, offering potential benefits for managing BPH[15].

Chronic Inflammation in BPH

Benign Prostatic Hyperplasia (BPH) is a common condition affecting aging men, characterized by the non-cancerous enlargement of the prostate gland. Chronic inflammation is a significant contributor to the disease's pathophysiology, with inflammation activating immune responses, alterations in cytokine profiles, oxidative stress, and tissue remodeling processes. Key mechanisms involved in chronic inflammation in BPH include pro-inflammatory cytokines, immune cell activation, oxidative stress, and fibrosis[16]. Pro-inflammatory cytokines are signaling molecules that mediate inflammation by promoting immune cell recruitment, activation, and tissue remodeling. In BPH tissues, elevated levels of key cytokines, including Interleukin-6 (IL-6), Interleukin-8 (IL-8), and Tumor Necrosis Factor-alpha (TNF-α), have been observed. These cytokines not only contribute to the inflammatory response but also play a crucial role in the pathogenesis of BPH[16, 17].

IL-6 is a potent mediator of inflammation and immune responses, promoting the activation of immune cells and the release of other pro-inflammatory cytokines and growth factors. IL-8, a chemokine that attracts neutrophils to the site of inflammation, plays a significant role in recruiting immune cells to the prostate in BPH, leading to increased prostate cell proliferation and the enlargement of the prostate gland[18]. TNF-α is a critical mediator of systemic and local inflammation, promoting the activation of immune cells and the production of other inflammatory mediators, further perpetuating the cycle of inflammation. Elevated TNF-α levels have been associated with increased prostate tissue remodeling, fibrosis, and smooth muscle cell proliferation, all contributing to prostate enlargement.

The activation of immune cells, including macrophages, T lymphocytes, and neutrophils, is crucial in the pathogenesis of Benign Prostatic Hyperplasia (BPH). These cells secrete pro-inflammatory cytokines and growth factors that promote tissue remodeling and prostate cell proliferation. Th1 and Th17 cells are involved in the pathogenesis of BPH, with Th1 cells releasing IFN-γ and Th17 cells producing IL-17, which has been linked to the recruitment of neutrophils and other immune cells[19]. Neutrophils are recruited to the prostate by IL-8, facilitating the recruitment of neutrophils and releasing enzymes and ROS, which can induce tissue damage and inflammation. Over time, this chronic influx of neutrophils results in the remodeling of prostate tissues, contributing to the development of fibrosis in BPH. The activation of these immune cells leads to the release of a wide array of cytokines, enzymes, and growth factors, which not only sustain the inflammatory response but also stimulate the processes of fibrosis

and tissue remodeling, further contributing to the enlargement of the prostate[19]. Oxidative stress, a condition characterized by an imbalance between the production of ROS and the antioxidant defense mechanisms of the cell, plays a pivotal role in cellular damage and tissue remodeling[1, 20]. In the context of BPH, oxidative stress-induced damage leads to the dysfunction of prostatic cells and accelerates the progression of the disease. Oxidative stress results in the excessive production of reactive oxygen species (ROS), which are highly reactive molecules capable of causing cellular damage. In the prostate, ROS can damage cellular components such as lipids, proteins, and DNA, leading to cell death or dysfunction. This damage triggers a cascade of inflammatory responses that contribute to the development of BPH.

Fibrosis, the process of excessive accumulation of extracellular matrix (ECM) components, such as collagen, in response to tissue injury, is a key role in BPH progression. Chronic inflammation activates fibroblasts, the key cells responsible for ECM production. Inflammatory cytokines like TGF-β stimulate fibroblasts to produce collagen and other ECM components, leading to fibrosis and tissue stiffening, obstruction of the urethra, and worsening urinary symptoms[21]. The interaction between inflammation and fibrosis is bidirectional in BPH, with inflammatory cytokines like IL-6 and TNF-α not only promoting immune cell recruitment but also stimulating fibroblast activity and ECM production. This fibrotic environment further perpetuates inflammation by trapping immune cells in the prostate, creating a vicious cycle that drives BPH progression. Addressing chronic inflammation and oxidative stress may represent a promising strategy for slowing the progression of BPH and improving patient outcomes[22].

Growth Factor Signaling Pathways Growth Factor Signaling Pathways

Growth factors are proteins that regulate cellular processes, such as proliferation, survival, differentiation, and migration. They are crucial for tissue development, wound healing, and the maintenance of homeostasis. Dysregulation of growth factor signaling pathways often leads to diseases, including cancer, fibrosis, and developmental disorders[23]. Here, we discuss three key growth factor families: Fibroblast Growth Factors (FGFs), Transforming Growth Factor-Beta (TGF-β), and Insulin-like Growth Factors (IGFs), with emphasis on their roles in stromal proliferation, extracellular matrix (ECM) deposition, epithelial-mesenchymal transition (EMT), fibrosis, and epithelial proliferation and survival[24].

Fibroblast Growth Factors (FGFs)

Fibroblast Growth Factors (FGFs) are a large family of growth factors that include over 20 members, involved in diverse biological processes such as angiogenesis, wound healing, tissue regeneration, and developmental processes. FGFs bind to FGF receptors (FGFRs) on the surface of target cells, activating intracellular signaling pathways that regulate cellular growth, differentiation, and migration[25, 26].

FGFs in Stromal Proliferation and Extracellular Matrix Deposition

In the context of stromal proliferation and extracellular matrix (ECM) deposition, FGFs play a vital role in tissue remodeling. The stromal compartment, consisting of fibroblasts, endothelial cells, and other mesenchymal cells, provides structural support to the tissue and is involved in wound healing and tumor progression. FGFs promote the proliferation of fibroblasts, which are key cells in ECM production[27]. Fibroblasts produce ECM proteins such as collagen, elastin, and fibronectin, which provide scaffolding for tissue integrity and are essential for cellular signaling and communication. FGF signaling enhances the synthesis and deposition of these ECM components, making it critical for both normal tissue repair and pathological conditions like fibrosis and tumor stroma formation[27]. Additionally, FGF signaling helps recruit endothelial cells to proliferate and form blood vessels (angiogenesis), which supplies nutrients and oxygen to the growing tissue or tumor. The interaction between FGF signaling and ECM deposition influences tissue structure and function, contributing to the regulation of cell behavior and tissue homeostasis.

Transforming Growth Factor-Beta (TGF-β)

Transforming Growth Factor-Beta (TGF-β) is a multifaceted cytokine family that regulates a wide range of cellular processes, including growth, differentiation, apoptosis, and immune responses. TGF-β signals through a complex receptor system involving type I and type II receptors, which activate downstream signaling pathways like the Smad pathway[27, 28].

TGF-β Signaling in Epithelial-Mesenchymal Transition (EMT) and Fibrosis

TGF-β is a key regulator of epithelial-mesenchymal transition (EMT), a process where epithelial cells lose their polarity and adhesion to acquire mesenchymal traits, such as increased motility and invasiveness. This process is essential during development, wound healing, and tissue fibrosis. However, aberrant TGF-β signaling is also implicated in pathological EMT, such as in cancer metastasis, where epithelial cells acquire migratory properties and invade surrounding tissues[28]. In fibrosis, TGF-β plays a central role by promoting

the activation of fibroblasts into myofibroblasts, which are highly proliferative and contribute to excessive ECM deposition. This results in the thickening and scarring of tissues. TGF-β-induced EMT and fibroblast activation are critical steps in the progression of diseases like pulmonary fibrosis, liver cirrhosis, and kidney fibrosis.

The TGF-β signaling pathway also regulates the synthesis of ECM proteins, including collagen and fibronectin, and inhibits their degradation by regulating matrix metalloproteinases (MMPs). As a result, TGF-β contributes to the fibrotic response by balancing ECM production and degradation[28].

Insulin-like Growth Factors (IGFs)

Insulin-like Growth Factors (IGFs), primarily IGF-1 and IGF-2, are peptide hormones that share structural similarity with insulin. They are produced in response to growth hormone (GH) stimulation and are crucial for regulating growth and metabolism. IGFs exert their effects through IGF receptors (IGF-1R and IGF-2R) on the cell surface, activating signaling pathways that regulate cell growth, survival, and differentiation[29].

Role of IGFs in Epithelial Proliferation and Survival

IGFs are essential for normal growth and development, particularly in tissues with high proliferative activity, such as epithelial tissues. IGF signaling promotes epithelial cell proliferation by activating the PI3K/Akt and Ras/Raf/MEK/ERK pathways, which regulate cell cycle progression and inhibit apoptosis. These pathways enhance the survival of epithelial cells, allowing tissues to grow and repair effectively[29]. In addition to their role in growth, IGFs influence the differentiation of various epithelial cell types. For example, in the mammary gland, IGF-1 stimulates the proliferation of epithelial cells, contributing to ductal and lobular development. Similarly, IGFs play a role in maintaining the integrity of the intestinal epithelium, where they regulate the renewal of intestinal crypt cells. Abnormal IGF signaling has been linked to the development of cancer, as excessive IGF activity can lead to uncontrolled cell proliferation, survival, and resistance to apoptosis. In particular, the upregulation of IGF-1R is associated with various malignancies, including breast, prostate, and colorectal cancers. Hence, IGF signaling pathways are not only crucial for normal epithelial homeostasis but also play a significant role in tumorigenesis[30].

Growth factor signaling pathways, including those mediated by FGFs, TGF-β, and IGFs, play crucial roles in regulating cellular processes like proliferation, differentiation, survival, and ECM deposition. These pathways are central to tissue development, repair, and homeostasis. However, dysregulation of these signaling cascades can contribute to pathological conditions such as fibrosis, cancer metastasis, and other growth disorders. Understanding the molecular mechanisms behind these pathways provides valuable insights into therapeutic strategies for diseases associated with abnormal growth factor signaling.

Cellular Mechanisms in BPH Progression

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, commonly occurring in aging men. Its pathogenesis is multifactorial, involving alterations at both the molecular and cellular levels. Two key cellular mechanisms play a significant role in the progression of BPH: stromal-epithelial interactions and the involvement of stem/progenitor cells. These mechanisms contribute to the imbalance between the proliferation of prostatic cells and the processes that normally regulate their growth, leading to the development of hyperplastic tissue in the prostate.

Stromal-Epithelial Interactions: The prostate is composed of two primary cell types: epithelial cells and stromal cells, both of which play essential roles in maintaining prostatic homeostasis. The epithelial cells form the glandular structures of the prostate, which are responsible for secretion, while the stromal cells, including smooth muscle and fibroblasts, provide structural support and regulate tissue remodeling. The interaction between these two cell types, known as stromal-epithelial crosstalk, is critical for normal prostate development, function, and homeostasis[31].

These interactions are mediated by various signaling pathways that regulate cell proliferation, differentiation, apoptosis, and extracellular matrix (ECM) remodeling. The stromal cells secrete growth factors, such as fibroblast growth factors (FGFs), transforming growth factor-beta (TGF-β), and platelet-derived growth factor (PDGF), which influence the behavior of the epithelial cells. In turn, the epithelial cells release factors such as cytokines and growth factors that affect the stromal cells' function, including smooth muscle contraction and collagen production. This dynamic crosstalk maintains a balance between cell growth and differentiation, ensuring that the prostate maintains its size and function throughout life. The ECM, which is a key component of the stromal compartment, also plays a crucial role in modulating these interactions by providing a scaffold for cellular adhesion and migration, as well as influencing cellular signaling through integrin receptors[31, 32].

Dysregulation of Stromal-Epithelial Interactions in BPH

In BPH, the normal stromal-epithelial interactions are disrupted, leading to an imbalance in cellular proliferation and differentiation. Several factors contribute to this dysregulation[33, 34]:

Increased Growth Factor Secretion: In BPH, there is an overproduction of growth factors, particularly androgens and their metabolites, which stimulate both stromal and epithelial cell proliferation. This leads to an increase in stromal cell number and smooth muscle cell hypertrophy, contributing to the enlargement of the prostate gland. Furthermore, pro-inflammatory cytokines released by immune cells in the stroma can exacerbate the proliferative response in the epithelium.

Altered ECM Remodeling: In BPH, the ECM undergoes pathological remodeling, with an increase in collagen deposition and fibrotic tissue formation in the stroma. This alters the biomechanical properties of the prostate, affecting stromal-epithelial signaling. The ECM proteins, such as collagen and fibronectin, can interfere with cellular communication, promoting the proliferation and survival of both stromal and epithelial cells, thus contributing to hyperplasia.

Epithelial-Mesenchymal Transition (EMT): EMT is a process by which epithelial cells lose their characteristic markers and gain mesenchymal properties, becoming more migratory and invasive. This phenomenon is observed in BPH, particularly in areas where the epithelial cells are exposed to altered stromal signaling. The activation of EMT pathways in the epithelial cells contributes to their uncontrolled proliferation and the formation of hyperplastic nodules. The dysregulated stromal-epithelial interactions in BPH ultimately lead to the development of a hyperplastic prostate with increased epithelial and stromal cell numbers. This imbalance disrupts prostatic homeostasis and results in the clinical manifestations of BPH, such as urinary symptoms due to prostate enlargement and compression of the urethra.

Role of Stem/Progenitor Cells

Contribution of Stem Cells to Prostatic Hyperplasia

Stem cells and progenitor cells are undifferentiated cells with the capacity to self-renew and differentiate into various specialized cell types. In the prostate, a small population of stem/progenitor cells resides within the basal epithelial compartment, capable of regenerating both the epithelial and stromal compartments during normal tissue maintenance and repair. These cells are also involved in the pathogenesis of BPH, where they contribute to abnormal prostate growth and the progression of hyperplasia[34].

In BPH, the proliferation of stem and progenitor cells is thought to play a central role in the development of enlarged prostatic tissue. These cells may be activated by various signaling pathways, including androgen receptor signaling and growth factors such as fibroblast growth factors (FGFs), epidermal growth factor (EGF), and insulin-like growth factors (IGFs), which are overexpressed in the stroma and epithelium of BPH tissues. As these stem/progenitor cells divide and differentiate, they give rise to a large number of progeny, including both stromal a nd epithelial cells. The resulting excess of these cells contributes to the overall enlargement of the prostate and the formation of hyperplastic nodules[35].

Evidence of Stem Cell Niches in BPH Tissues

Emerging evidence suggests that stem cell niches, microenvironments where stem cells reside and are regulated, are present in BPH tissues. These niches are located in specific areas of the prostate, primarily in the basal layer of the epithelium and within the stroma, where stem and progenitor cells interact with their surrounding matrix and stromal cells. In BPH, the stem/progenitor cell niches become dysregulated[36]. The normal signals that regulate stem cell quiescence and differentiation are altered, leading to the expansion of the stem cell pool. Studies have shown that there is an increase in the number of basal and intermediate cells in BPH tissues, which are likely derived from activated stem cells. Moreover, the stroma in BPH tissues exhibits a high degree of fibrosis, which can affect stem cell behavior and promote aberrant cell proliferation[36].

Recent studies utilizing markers of prostate stem cells, such as P63, CD44, and α6 integrin, have identified stem cell populations in BPH tissues that are associated with hyperplastic growth. Additionally, experiments involving prostate tissue from BPH patients have demonstrated the ability of stem cells from these tissues to generate both epithelial and stromal components in vitro, supporting the notion that these cells are critical contributors to the disease. Stem cell-mediated tissue remodeling in BPH may also be influenced by changes in the local microenvironment, including alterations in androgen levels, inflammatory signals, and growth factor expression[37]. The accumulation of mutations in stem/progenitor cells over time may also lead to the establishment of a "progenitor pool" that contributes to the persistence of BPH growth even after androgen deprivation. The progression of BPH is driven by complex cellular mechanisms, with stromal-epithelial interactions and the activity of stem/progenitor cells being central to disease development. Dysregulated stromal-epithelial signaling, altered ECM remodeling, and the expansion of stem cell populations contribute to abnormal cell proliferation and prostate enlargement. Understanding these cellular mechanisms offers potential therapeutic targets for the treatment of BPH, including approaches aimed at restoring normal stromal-epithelial communication and controlling the activity of stem/progenitor cells to prevent further hyperplastic growth[37].

Molecular Pathways and Therapeutic Targets

Key Molecular Pathways in Benign Prostatic Hyperplasia (BPH)[38, 39].

BPH, characterized by the non-cancerous enlargement of the prostate, is associated with several molecular pathways that regulate cellular proliferation, inflammation, and tissue remodeling. These molecular events drive the pathogenesis of BPH and serve as potential therapeutic targets.

PI3K/AKT/mTOR Pathway and Its Role in Cellular Proliferation

The **PI3K/AKT/mTOR pathway** plays a pivotal role in regulating cell growth, survival, and proliferation, all of which are critical in BPH development.

PI3K (Phosphoinositide 3-kinase) activates AKT (also known as protein kinase B), which then triggers downstream signaling events that promote cell cycle progression and survival.

The activation of AKT leads to the activation of **mTOR (mechanistic target of rapamycin)**, a central regulator of cell metabolism, growth, and proliferation. The mTOR pathway is involved in protein synthesis and cell growth, processes that are often dysregulated in BPH, leading to excessive prostate cell growth.

Overactivation of the **PI3K/AKT/mTOR signaling axis** has been implicated in the increased proliferation of prostate stromal and epithelial cells, contributing to prostate enlargement. This makes this pathway a critical target for therapeutic intervention in BPH.

Therapeutic strategies targeting this pathway could involve the use of inhibitors of PI3K, AKT, or mTOR, all of which have shown promise in preclinical studies for slowing down the excessive cellular proliferation seen in BPH.

NF-κB Pathway in Inflammation and Immune Response

The **NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)** signaling pathway is a key mediator of inflammation and immune responses. Chronic inflammation is a hallmark of BPH, and the NF-κB pathway is central to this process.

Inflammatory cytokines such as **TNF-α (tumor necrosis factor-alpha)** and **IL-1β (interleukin-1 beta)** activate NF-κB, which in turn leads to the transcription of genes involved in the inflammatory response.

Activated NF-κB promotes the production of pro-inflammatory mediators, such as **COX-2 (cyclooxygenase-2)**, which can lead to tissue damage and cellular stress, contributing to the pathogenesis of BPH.

The presence of infiltrating immune cells, including T lymphocytes and macrophages, further exacerbates the inflammatory microenvironment in the prostate tissue.

Targeting the NF-κB pathway with specific inhibitors could reduce inflammation in BPH, potentially alleviating symptoms and preventing further prostate growth. NF-κB inhibitors, such as **BAY 11-7082** and **parthenolide**, are under investigation as potential treatments for inflammatory diseases and BPH.

Potential Therapeutic Targets

The molecular understanding of BPH pathogenesis has led to the identification of several therapeutic targets. These targets aim to reduce cellular proliferation, modulate inflammation, and block abnormal signaling pathways that contribute to prostate growth.

Targeting Androgen Receptor Signaling

The role of **androgens** (male hormones like testosterone) in BPH is well-established, with androgens stimulating prostate growth through the activation of the **androgen receptor (AR)**.

Androgen receptor signaling plays a crucial role in regulating prostate cell proliferation and survival. In BPH, an overexpression or hypersensitivity of the AR leads to an abnormal response to circulating androgens.

5α-reductase inhibitors, such as **finasteride** and **dutasteride**, are used to reduce the conversion of testosterone to its more potent form, dihydrotestosterone (DHT), and consequently reduce AR signaling in the prostate.

Additionally, **AR antagonists**, such as **enzalutamide**, are being explored for their ability to block AR signaling, thus preventing prostate cell proliferation.

These interventions help to slow the progression of BPH and manage symptoms by reducing the influence of androgens on prostate tissue.

Anti-inflammatory Agents and Their Potential

Chronic inflammation plays a significant role in the development of BPH. Targeting inflammation could provide a therapeutic strategy for reducing prostate enlargement and improving symptoms.

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as **ibuprofen**, can inhibit COX enzymes and reduce the production of inflammatory mediators. Although not commonly used for BPH specifically, their anti-inflammatory properties could potentially alleviate BPH-related symptoms.

Corticosteroids and other immunomodulatory agents may also be considered to reduce the inflammatory response, although long-term use is generally avoided due to side effects.

Natural anti-inflammatory agents, including flavonoids and polyphenols from medicinal plants, have shown promise in preclinical studies for their ability to modulate immune responses and reduce inflammation in the prostate.

Targeting inflammation could reduce the inflammatory signaling in BPH tissues, providing

an adjunctive approach alongside androgen suppression.

Inhibitors of Growth Factor Signaling Pathways

Growth factors play a crucial role in regulating prostate cell proliferation. Abnormal activation of growth factor signaling pathways can contribute to the excessive growth of the prostate tissue observed in BPH.

The **epidermal growth factor receptor (EGFR)** and **vascular endothelial growth factor (VEGF)** are examples of growth factors implicated in BPH. Overexpression of EGFR and VEGF in prostate tissues has been linked to increased angiogenesis (formation of new blood vessels) and cellular proliferation.

Inhibitors of growth factor signaling, such as **EGFR inhibitors** (e.g., **gefitinib**) and **VEGF inhibitors** (e.g., **bevacizumab**), could block the signaling pathways that drive abnormal growth in BPH.

Inhibition of growth factor signaling may help in reducing the growth of prostate tissue and addressing the underlying pathology of BPH.

Evidence of Stem Cell Niches in BPH Tissues

Recent studies have identified the presence of **stem cell niches** within BPH tissues. These niches contain progenitor cells that may contribute to abnormal prostate growth and tissue remodeling.

Prostatic stem cells can differentiate into various cell types, including epithelial and stromal cells, and play a crucial role in tissue regeneration. In BPH, dysregulated stem cell activity may contribute to the continuous growth of prostate tissue.

Targeting **prostatic stem cell niches** may provide a novel therapeutic approach for halting the abnormal growth of prostate tissue. This could involve targeting signaling pathways that regulate stem cell maintenance and differentiation, such as the **Wnt/β-catenin** and **Notch pathways**. Research into stem cell therapies and their modulation holds promise for treating BPH by addressing its root cause—excessive cellular proliferation driven by stem cell activity.

The molecular understanding of BPH has led to the identification of several promising therapeutic targets, including androgen receptor signaling, growth factor pathways, inflammatory mediators, and stem cell niches. Therapeutic strategies targeting these pathways offer the potential to slow disease progression, reduce symptoms, and improve the quality of life for individuals affected by BPH. As research continues, new therapies may emerge to more effectively manage this common condition.

Future Research Directions

To further advance the understanding and treatment of BPH, several future research directions should be explored:

1. **Stromal-Epithelial Interactions**: While the role of stromal-epithelial interactions in BPH progression is recognized, there is still much to learn about the precise mechanisms involved. Investigating how these interactions are regulated at the molecular level, and how they contribute to cellular proliferation, fibrosis, and inflammation, could provide critical insights into BPH pathogenesis. Furthermore, exploring how these interactions differ in BPH and other prostate disorders, such as prostate cancer, may help identify unique therapeutic targets.
2. **Novel Biomarkers**: Identifying biomarkers for BPH progression would significantly improve diagnosis, prognosis, and treatment monitoring. Biomarkers could help to stratify patients based on the severity of their condition, predict disease progression, and monitor the effectiveness of therapies. Exploring circulating biomarkers, such as cytokines, growth factors, and miRNAs, as well as tissue-based biomarkers, could be instrumental in achieving these goals.
3. **Genetic and Epigenetic Factors**: There is emerging evidence that genetic and epigenetic factors contribute to BPH susceptibility and progression. Future studies should focus on identifying genetic polymorphisms and epigenetic alterations that influence the development of BPH. Understanding the genetic basis of BPH could lead to the development of personalized treatment strategies tailored to the patient's genetic profile.
4. **Targeted Therapies and Drug Development**: Further research is needed to identify and develop novel targeted therapies that specifically modulate the key molecular pathways involved in BPH. This could include the development of small molecules, biologics, or gene therapies that target androgen receptor signaling, growth factor pathways, or inflammatory processes. Additionally, combination therapies that address multiple aspects of BPH progression, such as androgen blockade and anti-inflammatory treatment, may offer more effective management options.

CONCLUSION

Benign prostatic hyperplasia (BPH) is an age-related disorder characterized by the enlargement of the prostate gland, leading to lower urinary tract symptoms. Understanding the cellular and

molecular mechanisms driving BPH progression is crucial for developing effective targeted therapies and improving patient outcomes. Key cellular processes involved in BPH progression include hormonal regulation, growth factors and cytokines, fibrosis and extracellular matrix remodeling, and stromal-epithelial interactions. Hormonal regulation involves the androgenic pathway, which converts testosterone into dihydrotestosterone (DHT) in the prostate, stimulating the growth of both stromal and epithelial cells. Elevated DHT levels have been implicated in BPH pathogenesis, with androgenic signaling driving prostate cell proliferation. Growth factors like FGF, VEGF, and TGF-β play crucial roles in stromal-epithelial interactions, promoting cellular proliferation, angiogenesis, and extracellular matrix remodeling. Inflammatory cytokines, such as interleukins and TNF-α, also contribute to BPH progression by stimulating inflammation and fibrosis. Fibrosis and extracellular matrix remodeling are hallmarks of BPH progression, with the accumulation of extracellular matrix components, particularly collagen, leading to fibrosis. Dysregulation of matrix metalloproteinases and their inhibitors (TIMPs) is often observed in BPH, resulting in abnormal ECM remodeling. The interplay between stromal and epithelial cells is a key feature of BPH progression, with stromal cells secreting growth factors and cytokines that influence epithelial cell growth, while epithelial cells release factors that affect stromal cell behavior. This bidirectional communication creates a microenvironment that promotes abnormal cellular proliferation, inflammation, and fibrosis, all contributing to prostate enlargement. In conclusion, the progression of BPH is driven by a combination of hormonal, growth factor, inflammatory, and stromal-epithelial signaling pathways. A deeper understanding of these mechanisms will pave the way for the development of more effective and targeted therapies, ultimately improving the quality of life for patients with BPH. Future research should focus on further elucidating the stromal-epithelial interactions and identifying novel biomarkers to enhance diagnosis and treatment outcomes. With advances in molecular biology, genomics, and drug development, more personalized and effective therapies for BPH are on the horizon.

REFERENCES

1. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Itodo, M.O., Agada, S.A., Umoru, G.U., Obeten, U.N., Nwobodo, V.O.G., Nwadum, S.K., Udoudoh, M.P.: Xylopia aethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences NU. 14, 477–485 (2024). https://doi.org/10.1055/s-0043-1777836
2. Welén, K., Damber, J.-E.: Androgens, aging, and prostate health. Rev Endocr Metab Disord. 23, 1221–1231 (2022). https://doi.org/10.1007/s11154-022-09730-z
3. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Chinedum, K.E., Agu, P., Nwobodo, V.: In Vivo and in Silico Assessment of Ameliorative Effects of Xylopia aethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia. Pharmaceutical Fronts. 05, e64–e76 (2023). https://doi.org/10.1055/s-0043-1768477
4. Farrant, M., Page, S.T.: Androgens and Benign Prostatic Hyperplasia☆. In: Huhtaniemi, I. and Martini, L. (eds.) Encyclopedia of Endocrine Diseases (Second Edition). pp. 775–783. Academic Press, Oxford (2018)
5. Cao, D., Sun, R., Peng, L., Li, J., Huang, Y., Chen, Z., Chen, B., Li, J., Ai, J., Yang, L., Liu, L., Wei, Q.: Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging. Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.842008
6. Fu, X., Wang, Y., Lu, Y., Liu, J., Li, H.: Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. Life Sciences. 358, 123192 (2024). https://doi.org/10.1016/j.lfs.2024.123192
7. Lokeshwar, S.D., Harper, B.T., Webb, E., Jordan, A., Dykes, T.A., Neal, D.E., Terris, M.K., Klaassen, Z.: Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 8, 529–539 (2019). https://doi.org/10.21037/tau.2019.10.01
8. Ye, Z., Wang, J., Xiao, Y., Luo, J., Xu, L., Chen, Z.: Global burden of benign prostatic hyperplasia in males aged 60–90 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urology. 24, 193 (2024). https://doi.org/10.1186/s12894-024-01582-w
9. Lim, K.B.: Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 4, 148–151 (2017). https://doi.org/10.1016/j.ajur.2017.06.004

10. Awedew, A.F., Han, H., Abbasi, B., Abbasi-Kangevari, M., Ahmed, M.B., Almidani, O., Amini, E., Arabloo, J., Argaw, A.M., Athari, S.S., Atlaw, D., Banach, M., Barrow, A., Bhagavathula, A.S., Bhojaraja, V.S., Bikbov, B., Bodicha, B.B.A., Butt, N.S., Santos, F.L.C. dos, Dadras, O., Dai, X., Doan, L.P., Eftekharzadeh, S., Fatehizadeh, A., Garg, T., Gebremeskel, T.G., Getachew, M.E., Ghamari, S.-H., Gilani, S.A., Golechha, M., Gupta, V.B., Gupta, V.K., Hay, S.I., Hosseini, M.-S., Hosseinzadeh, M., Humayun, A., Ilic, I.M., Ilic, M.D., Ismail, N.E., Jakovljevic, M., Jayaram, S., Jazayeri, S.B., Jema, A.T., Kabir, A., Karaye, I.M., Khader, Y.S., Khan, E.A., Landires, I., Lee, S., Lee, S.W.H., Lim, S.S., Lobo, S.W., Majeed, A., Malekpour, M.-R., Malih, N., Malik, A.A., Nasab, E.M., Mestrovic, T., Michalek, I.M., Mihrtie, G.N., Mirza-Aghazadeh-Attari, M., Misganaw, A.T., Mokdad, A.H., Molokhia, M., Murray, C.J.L., Swamy, S.N., Nguyen, S.H., Nowroozi, A., Nuñez-Samudio, V., Owolabi, M.O., Pawar, S., Perico, N., Rawaf, D.L., Rawaf, S., Rawassizadeh, R., Remuzzi, G., Sahebkar, A., Sampath, C., Shetty, J.K., Sibhat, M.M., Singh, J.A., Tan, K.-K., Temesgen, G., Tolani, M.A., Tovani-Palone, M.R., Tahbaz, S.V., Valizadeh, R., Vo, B., Vu, L.G., Yang, L., Yazdanpanah, F., Yigit, A., Yiğit, V., Yunusa, I., Zahir, M., Vos, T., Dirac, M.A.: The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Healthy Longevity. 3, e754–e776 (2022). https://doi.org/10.1016/S2666-7568(22)00213-6
11. Ajayi, A., Abraham, K.: Understanding the role of estrogen in the development of benign prostatic hyperplasia. African Journal of Urology. 24, 93–97 (2018). https://doi.org/10.1016/j.afju.2018.01.005
12. La Vignera, S., Condorelli, R.A., Russo, G.I., Morgia, G., Calogero, A.E.: Endocrine control of benign prostatic hyperplasia. Andrology. 4, 404–411 (2016). https://doi.org/10.1111/andr.12186
13. Chen, P., Li, B., Ou-Yang, L.: Role of estrogen receptors in health and disease. Front. Endocrinol. 13, (2022). https://doi.org/10.3389/fendo.2022.839005
14. Chen, B., Cao, D., Chen, Z., Huang, Y., Lin, T., Ai, J., Liu, L., Wei, Q.: Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology. 9, 32231–32331 (2020). https://doi.org/10.21037/tau.2020.02.08
15. Dong, H., Zeng, X., Xu, J., He, C., Sun, Z., Liu, L., Huang, Y., Sun, Z., Cao, Y., Peng, Z., Qiu, Y., Yu, T.: Advances in immune regulation of the G protein-coupled estrogen receptor.International Immunopharmacology. 136, 112369 (2024). https://doi.org/10.1016/j.intimp.2024.112369
16. Chughtai, B., Lee, R., Te, A., Kaplan, S.: Role of Inflammation in Benign Prostatic Hyperplasia. Rev Urol. 13, 147–150 (2011)
17. Naiyila, X., Li, J., Huang, Y., Chen, B., Zhu, M., Li, J., Chen, Z., Yang, L., Ai, J., Wei, Q., Liu, L., Cao, D.: A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia. Journal of Clinical Medicine. 12, 1821(2023). https://doi.org/10.3390/jcm12051821
18. Ullah, A., Chen, Y., Singla, R.K., Cao, D., Shen, B.: Pro-inflammatory cytokines and CXC chemokines as game-changer in age-associated prostate cancer and ovarian cancer: Insights from preclinical and clinical studies' outcomes. Pharmacological Research. 204, 107213 (2024). https://doi.org/10.1016/j.phrs.2024.107213
19. Radej, S., Szewc, M., Maciejewski, R.: Prostate Infiltration by Treg and Th17 Cells as an Immune Response to Propionibacterium acnes Infection in the Course of Benign Prostatic Hyperplasia and Prostate Cancer. International Journal of Molecular Sciences. 23, 8849 (2022). https://doi.org/10.3390/ijms23168849
20. Pizzino, G., Irrera, N., Cucinotta, M., Pallio, G., Mannino, F., Arcoraci, V., Squadrito, F., Altavilla, D., Bitto, A.: Oxidative Stress: Harms and Benefits for Human Health. Oxidative Medicine and Cellular Longevity. 2017, 8416763 (2017). https://doi.org/10.1155/2017/8416763
21. Antar, S.A., Ashour, N.A., Marawan, M.E., Al-Karmalawy, A.A.: Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation. Int J Mol Sci. 24, 4004 (2023). https://doi.org/10.3390/ijms24044004
22. Ku, J.C., Raiten, J., Li, Y.: Understanding fibrosis: Mechanisms, clinical implications, current therapies, and prospects for future interventions. Biomedical Engineering Advances. 7, 100118 (2024). https://doi.org/10.1016/j.bea.2024.100118
23. Deng, Z., Fan, T., Xiao, C., Tian, H., Zheng, Y., Li, C., He, J.: TGF-β signaling in health, disease and therapeutics. Signal Transduct

Target Ther. 9, 61 (2024). https://doi.org/10.1038/s41392-024-01764-w
24. Farooq, M., Khan, A.W., Kim, M.S., Choi, S.: The Role of Fibroblast Growth Factor (FGF) Signaling in Tissue Repair and Regeneration. Cells. 10, 3242 (2021). https://doi.org/10.3390/cells10113242
25. Zlibut, A., Bocsan, I.C., Agoston-Coldea, L.: Chapter Five - Pentraxin-3 and endothelial dysfunction. In: Makowski, G.S. (ed.) Advances in Clinical Chemistry. pp. 163–179. Elsevier (2019)
26. Ornitz, D.M., Itoh, N.: The Fibroblast Growth Factor signaling pathway. WIREs Developmental Biology. 4, 215–266 (2015). https://doi.org/10.1002/wdev.176
27. Yuan, Z., Li, Y., Zhang, S., Wang, X., Dou, H., Yu, X., Zhang, Z., Yang, S., Xiao, M.: Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Molecular Cancer. 22, 48 (2023). https://doi.org/10.1186/s12943-023-01744-8
28. Baba, A.B., Rah, B., Bhat, Gh.R., Mushtaq, I., Parveen, S., Hassan, R., Hameed Zargar, M., Afroze, D.: Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within. Front Pharmacol. 13, 791272 (2022). https://doi.org/10.3389/fphar.2022.791272
29. Gonchar, I.V., Lipunov, A.R., Afanasov, I.M., Larina, V., Faller, A.P., Kibardin, A.V.: Platelet rich plasma and growth factors cocktails for diabetic foot ulcers treatment: State of art developments and future prospects. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 12, 189–194 (2018). https://doi.org/10.1016/j.dsx.2017.09.007
30. Maki, R.G.: Small Is Beautiful: Insulin-Like Growth Factors and Their Role in Growth, Development, and Cancer. J Clin Oncol. 28, 4985–4995(2010). https://doi.org/10.1200/JCO.2009.27.5040
31. Bonollo, F., Thalmann, G.N., Kruithof-de Julio, M., Karkampouna, S.: The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. Cancers (Basel). 12, 1887(2020). https://doi.org/10.3390/cancers12071887
32. Di Carlo, E., Sorrentino, C.: The multifaceted role of the stroma in the healthy prostate and prostate cancer. Journal of Translational Medicine. 22, 825 (2024). https://doi.org/10.1186/s12967-024-05564-2
33. Liu, J., Zhang, J., Fu, X., Yang, S., Li, Y., Liu, J., DiSanto, M.E., Chen, P., Zhang, X.: The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. Int J Mol Sci. 24, 2870 (2023). https://doi.org/10.3390/ijms24032870
34. Fu, X., Wang, Y., Lu, Y., Liu, J., Li, H.: Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. Life Sciences. 358, 123192 (2024). https://doi.org/10.1016/j.lfs.2024.123192
35. Prajapati, A., Gupta, S., Mistry, B., Gupta, S.: Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts. BioMed Research International. 2013, 107954(2013). https://doi.org/10.1155/2013/107954
36. Prajapati, A., Gupta, S., Mistry, B., Gupta, S.: Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts. Biomed Res Int. 2013, 107954 (2013). https://doi.org/10.1155/2013/107954
37. Joseph, D.B., Turco, A.E., Vezina, C.M., Strand, D.W.: Progenitors in prostate development and disease. Developmental Biology. 473, 50–58 (2021). https://doi.org/10.1016/j.ydbio.2020.11.012
38. Ke, Z.-B., Cai, H., Wu, Y.-P., Lin, Y.-Z., Li, X.-D., Huang, J.-B., Sun, X.-L., Zheng, Q.-S., Xue, X.-Y., Wei, Y., Xu, N.: Identification of key genes and pathways in benign prostatic hyperplasia. J Cell Physiol. 234, 19942–19950(2019). https://doi.org/10.1002/jcp.28592
39. Chen, Z., Ge, M.: Discovering pathways in benign prostate hyperplasia: A functional genomics pilot study. Exp Ther Med. 21, 242 (2021). https://doi.org/10.3892/etm.2021.9673

CITE AS: Mugisha Emmanuel K. (2025). Pathophysiology of Benign Prostatic Hyperplasia: Cellular and Molecular Mechanisms. IDOSR JOURNAL OF APPLIED SCIENCES 10(1):26-35.
https://doi.org/10.59298/IDOSRJAS/2025/101.263500